Indolent Lymphoma
From the Journals
Bortezomib may unlock resistance in WM with mutations
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
Conference Coverage
Consider treatment, testing when CLL symptoms emerge
CHICAGO – Predictive tests should be conducted before beginning therapy.
Conference Coverage
CLL: The initial work-up
CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.
Conference Coverage
Zanubrutinib looks ‘robust’ in Waldenström macroglobulinemia
Phase 1 data shows a high overall response rate to the BTK inhibitor.
Conference Coverage
Variant not linked to CLL in Southeast Europe
DUBROVNIK, CROATIA – The PTPN22 R620W polymorphism was not associated with CLL in patients from Southeast Europe.
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
From the Journals
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.
News
Ibrutinib plus obinutuzumab gets priority review in CLL/SLL
This sets the stage for
Conference Coverage
Updated ThroLy system predicts need for thromboprophylaxis
DUBROVNIK, CROATIA – The revised ThroLy scoring system offers a lymphoma-specific system to predict thromboembolic events.
Conference Coverage
Some mutation testing can be useful at CLL diagnosis
CHICAGO –
From the Journals
Frontline rituximab shows long-term success in indolent lymphoma
A study with 10-year follow-up data suggests that chemotherapy can be delayed in symptomatic indolent lymphoma patients.